Nykode Therapeutics A Equity 2024

Nykode Therapeutics A Aktienanalyse

What does Nykode Therapeutics A do?

Vaccibody AS is a Norwegian biotechnology company that was founded in 2007. It is headquartered in Oslo and currently employs about 40 people. The company specializes in the development of individualized vaccines based on DNA-based technology. The idea for founding Vaccibody came about when the two founders, Agnete Fredriksen and Bjarne Bogen, were collaborating at the University of Oslo. They wanted to develop a method to personalize vaccines in order to increase their effectiveness and compatibility. Their discovery is based on the fact that T-cells play an important role in the immune system and can recognize specific target proteins produced by cancer cells or viruses. Vaccibody's business model is based on the development of individualized vaccines based on DNA-based technology. The company has several different areas, including cancer immunotherapy, infectious diseases, and personalized medicine. Vaccibody's vaccines can be used for various types of cancer, such as lung, breast, and prostate cancer. Vaccibody offers a range of products, including a vaccine against HPV (human papillomavirus) that is approved for women aged 9 to 45. This vaccine aims to reduce the risk of cervical cancer. Another product from Vaccibody is the prostate cancer vaccine VCD-001. This vaccine uses the antigen PSA (prostate-specific antigen), which occurs on the surface of prostate cancer cells, to stimulate the patient's immune system. Vaccibody is also working on the development of vaccines against COVID-19 and has already achieved initial positive results in preclinical studies. As part of its personalized medicine division, Vaccibody offers the DNA platform VACCIBODY®, which is used to manufacture individualized DNA vaccines. This technology allows the vaccine to be tailored specifically to the needs of each patient. Vaccibody has achieved many important milestones since its inception. In 2018, the company received a $12.5 million investment to further develop its cancer immunotherapy platform. In 2020, Vaccibody received an additional $43.5 million investment to advance the development of its COVID-19 vaccine. Overall, Vaccibody has the potential to change the way vaccines are developed and used. DNA-based technology offers many advantages over conventional vaccines, especially in personalized medicine. Vaccibody is working hard to further develop its technology and bring its products to market in order to improve the lives of people around the world. Nykode Therapeutics A ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Nykode Therapeutics A's Equity

Nykode Therapeutics A's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Nykode Therapeutics A's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Nykode Therapeutics A's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Nykode Therapeutics A's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Nykode Therapeutics A’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Nykode Therapeutics A stock

What is the equity of Nykode Therapeutics A this year?

Nykode Therapeutics A has equity of 171.26 M USD this year.

What was the equity of Nykode Therapeutics A compared to the previous year?

The equity of Nykode Therapeutics A has increased/decreased by 9.07% increased compared to the previous year.

What impact does a high equity have on investors of Nykode Therapeutics A?

A high equity is advantageous for investors of Nykode Therapeutics A as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Nykode Therapeutics A?

A low equity can be a risk for investors of Nykode Therapeutics A, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Nykode Therapeutics A affect the company?

An increase in equity of Nykode Therapeutics A can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Nykode Therapeutics A affect the company?

A reduction in equity of Nykode Therapeutics A can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Nykode Therapeutics A?

Some factors that can affect the equity of Nykode Therapeutics A include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Nykode Therapeutics A so important for investors?

The equity of Nykode Therapeutics A is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Nykode Therapeutics A take to change the equity?

To change equity, Nykode Therapeutics A can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Nykode Therapeutics A pay?

Over the past 12 months, Nykode Therapeutics A paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nykode Therapeutics A is expected to pay a dividend of 0 USD.

What is the dividend yield of Nykode Therapeutics A?

The current dividend yield of Nykode Therapeutics A is .

When does Nykode Therapeutics A pay dividends?

Nykode Therapeutics A pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nykode Therapeutics A?

Nykode Therapeutics A paid dividends every year for the past 0 years.

What is the dividend of Nykode Therapeutics A?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nykode Therapeutics A located?

Nykode Therapeutics A is assigned to the 'Health' sector.

Wann musste ich die Aktien von Nykode Therapeutics A kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nykode Therapeutics A from 12/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.

When did Nykode Therapeutics A pay the last dividend?

The last dividend was paid out on 12/18/2024.

What was the dividend of Nykode Therapeutics A in the year 2023?

In the year 2023, Nykode Therapeutics A distributed 0 USD as dividends.

In which currency does Nykode Therapeutics A pay out the dividend?

The dividends of Nykode Therapeutics A are distributed in USD.